Skip to main content
SpringerLink
Log in

Bone-Modifying Agents and Anticancer Agents with Bone Effects

  • Chapter
  • First Online:
Book cover Management of Bone Metastases

Abstract

Bone metastases are virtually incurable resulting in significant disease morbidity, reduced quality of life, and mortality. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Increased understanding of the pathogenesis of bone disease has led to the discovery and clinical utility of bone-targeted agents other than bisphosphonates and denosumab, currently the standard of care in this setting.

In this chapter, we present the recent advances in molecular-targeted therapies focusing on therapies that inhibit bone resorption and/or stimulate bone formation and novel antitumor agents that exert significant effects on skeletal metastases, nowadays available in clinical practice or in phase of development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 2001;20:333–49.

    Article  CAS  PubMed  Google Scholar 

  2. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.

    Article  CAS  PubMed  Google Scholar 

  3. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15:57–62.

    Article  CAS  PubMed  Google Scholar 

  4. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10:169–80.

    Article  PubMed  Google Scholar 

  5. Kingsley LA, Fournier PG, Chirgwin JM, et al. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609–17.

    Article  CAS  PubMed  Google Scholar 

  6. Mercer RR, Miyasaka C, Mastro AM. Metastatic breast cancer cells suppress OBL adhesion and differentiation. Clin Exp Metastasis. 2004;21:427–35.

    Article  CAS  PubMed  Google Scholar 

  7. Bu G, Lu W, Liu CC, et al. Breast cancer-derived Dickkopf1 inhibits OBL differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer. 2008;123:1034–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mastro AM, Gay CV, Welch DR, et al. Breast cancer cells induce OBL apoptosis: a possible contributor to bone degradation. J Cell Biochem. 2004;91:265–76.

    Article  CAS  PubMed  Google Scholar 

  9. Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65:7554–60.

    Article  CAS  PubMed  Google Scholar 

  10. Hall CL, Kang S, MacDougald OA, et al. Role of Wnts in prostate cancer bone metastases. J Cell Biochem. 2006;97:661–72.

    Article  CAS  PubMed  Google Scholar 

  11. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev. 2006;25:521–9. https://doi.org/10.1007/s10555-006-9036-9.

    Article  PubMed  Google Scholar 

  12. Park SI, Soki FN, McCauley LK. Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron. 2011;4:237–46. https://doi.org/10.1007/s12307-011-0081-8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol. 2012;19:250–5. https://doi.org/10.1097/MOH.0b013e328353c714.

    Article  PubMed  CAS  Google Scholar 

  14. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285–93. https://doi.org/10.1038/nrc2621.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone. 2011;49:71–6.

    Article  CAS  PubMed  Google Scholar 

  17. Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12:6222s–30s.

    Article  CAS  PubMed  Google Scholar 

  18. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581–9.

    Article  CAS  PubMed  Google Scholar 

  19. Mönkkönen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006;147:437–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90:1133–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Coleman R, Gnant M, Morgan G, et al. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012;104:1059–67.

    Article  CAS  PubMed  Google Scholar 

  22. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012;2:CD003474.

    Google Scholar 

  23. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314–21.

    Article  CAS  PubMed  Google Scholar 

  24. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082–90.

    Article  CAS  PubMed  Google Scholar 

  25. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14:1399–405.

    Article  PubMed  Google Scholar 

  26. Heras P, Kritikos K, Hatzopoulos A, Georgopoulou AP. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. Eur J Cancer Care (Engl). 2009;18:653–6.

    Article  CAS  Google Scholar 

  27. Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246:67–74.

    Article  CAS  PubMed  Google Scholar 

  28. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59–65.

    Article  CAS  PubMed  Google Scholar 

  29. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer. 2001;88:701–7.

    PubMed  CAS  Google Scholar 

  30. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.

    Article  CAS  PubMed  Google Scholar 

  31. Martin M, Bell R, Bourgeois H, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18:4841–9.

    Article  CAS  PubMed  Google Scholar 

  32. Van Poznak CH, Von Roenn JH, Temin S. American Society of Clinical Oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract. 2011;7:117–21.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(suppl 3):iii124–i37.

    Article  PubMed  Google Scholar 

  34. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force report: bone health in cancer care. J Natl Compr Cancer Netw. 2013;11(suppl 3):S1–50. quiz S51

    Article  Google Scholar 

  35. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.

    Article  CAS  PubMed  Google Scholar 

  36. Saad F, Gleason DM, Murray R, et al. Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate carcinoma. J Natl Cancer Inst. 2004;96(11):879–82.

    Article  CAS  PubMed  Google Scholar 

  37. Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013;16(4):382–6. https://doi.org/10.1038/pcan.2013.35. Epub 2013 Oct 1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. James ND, Sydes MR, Clarke NW, Mason MD, STAMPEDE investigators, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Smith MR, Halabi S, Ryan CJ, Hussain A, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014;32(11):1143–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Liu XH, Kirschenbaum A, Yao S, et al. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology. 2005;146:1991–8.

    Article  CAS  PubMed  Google Scholar 

  41. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468:103–7.

    Article  CAS  PubMed  Google Scholar 

  42. Schramek D, Leibbrandt A, Sigl V, et al. OCL differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468:98–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Nguyen DX, Bos PD, Massagu J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–84.

    Article  CAS  Google Scholar 

  44. Loser K, Mehling A, Loeser S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med. 2006;12:1372–9.

    Article  CAS  PubMed  Google Scholar 

  45. Akiyama T, Shimo Y, Yanai H, et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity. 2008;29:423–37.

    Article  CAS  PubMed  Google Scholar 

  46. Knoop KA, Kumar N, Butler BR, et al. RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol. 2009;183:5738–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–32.

    Article  CAS  PubMed  Google Scholar 

  49. Lipton A, Fizazi K, Stopeck AT, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. 2016;53:75–83.

    Article  CAS  PubMed  Google Scholar 

  50. Smith MR, Saad F, Oudard S, Shore N, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31(30):3800–6.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Coffey K, Robson CN. Regulation of the androgen receptor by post-translational modifications. J Endocrinol. 2012;215:221–37.

    Article  CAS  PubMed  Google Scholar 

  53. Liu LL, Xie N, Sun S, et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2014;33:3140–50.

    Article  CAS  PubMed  Google Scholar 

  54. Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol. 2012;360:38–43.

    Article  CAS  PubMed  Google Scholar 

  55. Drake JM, Graham NA, Stoyanova T, et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A. 2012;109:1643–64.

    Article  PubMed  PubMed Central  Google Scholar 

  56. De Bono S, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.

    Article  CAS  PubMed  Google Scholar 

  59. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    Article  CAS  PubMed  Google Scholar 

  60. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    Article  CAS  PubMed  Google Scholar 

  61. Rowlands MG, Barrie SE, Chan F, et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem. 1995;38:4191–7.

    Article  CAS  PubMed  Google Scholar 

  62. O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol. 1994;50:267–73.

    Article  CAS  PubMed  Google Scholar 

  64. Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012;97:507–16.

    Article  CAS  PubMed  Google Scholar 

  65. Iuliani M, Pantano F, Buttigliero C, et al. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget. 2015;6(14):12520–8.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16:509–21.

    Article  CAS  PubMed  Google Scholar 

  68. Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (everolimus): pivotal role of the prenylation process. Cancer Res. 2010;70:10329–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNF-alpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003;10:1165–77.

    Article  CAS  PubMed  Google Scholar 

  70. Bertoldo F, Silvestris F, Ibrahim T, et al. Targeting bone metastatic cancer: role of the mTOR pathway. Biochim Biophys Acta. 2014;1845(2):248–54.

    PubMed  CAS  Google Scholar 

  71. Kneissel M, Luong-Nguyen NH, Baptist M, et al. Everolimus sup-presses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004;35:1144–56.

    Article  CAS  PubMed  Google Scholar 

  72. Mogi M, Kondo A. Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells. Biochem Biophys Res Commun. 2009;384:82–6.

    Article  CAS  PubMed  Google Scholar 

  73. Ory B, Moriceau G, Redini F, Heymann D. mTOR inhibitors(rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem. 2007;14:1381–7.

    Article  CAS  PubMed  Google Scholar 

  74. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

    Article  CAS  PubMed  Google Scholar 

  75. Gnant M, Baselga J, Rugo HS, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013;105:654–63.

    Article  CAS  PubMed  Google Scholar 

  76. Maass N, Harbeck N, Mundhenke C, et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol. 2013;139:2047–56.

    Article  CAS  PubMed  Google Scholar 

  77. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109:637–43.

    Article  CAS  PubMed  Google Scholar 

  78. Silberstein EB. Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J Nucl Med. 1996;37:249–52.

    PubMed  CAS  Google Scholar 

  79. James ND, Pirrie S, Barton D, et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). ASCO meeting abstract. J Clin Oncol. 2013;31(Suppl).

    Article  Google Scholar 

  80. Allen BJ. Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials. 2008;3:185–91.

    Article  CAS  PubMed  Google Scholar 

  81. Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–5.

    PubMed  CAS  Google Scholar 

  82. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94.

    Article  CAS  PubMed  Google Scholar 

  83. Larsen RH, Saxtorph H, Skydsgaard M, et al. Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology. In Vivo. 2006;20:325–31.

    PubMed  CAS  Google Scholar 

  84. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

    Article  CAS  PubMed  Google Scholar 

  85. Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406.

    Article  CAS  PubMed  Google Scholar 

  86. Gartrell BA, Coleman R, Efstathiou E, et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol. 2015;68(5):850–8.

    Article  PubMed  Google Scholar 

  87. Spencer GJ, Utting JC, Etheridge SL, et al. Wnt signalling in OBLs regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119:1283–96.

    Article  CAS  PubMed  Google Scholar 

  88. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114(2):371–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Iyer SP, Beck JT, Stewart AK, et al. A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014;167:366–75.

    Article  CAS  PubMed  Google Scholar 

  90. Zhang S, Zhau HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 2010;9:9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60:1113–7.

    Article  PubMed  Google Scholar 

  92. Adamopoulos IE, Xia Z, Lau YS, et al. Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis. Biochem Biophys Res Commun. 2006;350:478–83.

    Article  CAS  PubMed  Google Scholar 

  93. Aenlle KK, Curtis KM, Roos BA, et al. Hepatocyte growth factor and p38 promote osteogenic differentiation of human mesenchymal stem cells. Mol Endocrinol. 2014;28:722–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Chen HT, Tsou HK, Chang CH, et al. Hepatocyte growth factor increases osteopontin expression in human OBLs through PI3K, Akt, c-Src, and AP-1 signaling pathway. PLoS One. 2012;7:e38378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for OCLs and OBLs in vitro. Proc Natl Acad Sci U S A. 1996;93:7644–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412–9.

    Article  CAS  PubMed  Google Scholar 

  97. Smith MR, De Bono JS, Sternberg CN, et al. Final analysis of COMET-1: cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). In: 2015 genitourinary cancers symposium.

    Google Scholar 

  98. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814–23. https://doi.org/10.1056/NEJMoa1510016.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Santini D, Tonini G. Treatment of advanced renal-cell carcinoma. N Engl J Med. 2016;374:888–9. https://doi.org/10.1056/NEJMc1515613#SA2.

    Article  PubMed  Google Scholar 

  100. Motzer RJ, Escudier B, Choueiri TK. Treatment of advanced renal-cell carcinoma. N Engl J Med. 2016;374:889–90. https://doi.org/10.1056/NEJMc1515613.

    Article  PubMed  Google Scholar 

  101. Fioramonti M, Santini D, Iuliani M, et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. Oncotarget. 2017;8(12):20113–21. https://doi.org/10.18632/oncotarget.15390.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Campus Bio-Medico University of Rome, Rome, Italy

    Daniele Santini, Francesco Pantano, Michele Iuliani, Giulia Ribelli, Paolo Manca, Bruno Vincenzi & Giuseppe Tonini

Authors
  1. Daniele Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Pantano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Iuliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giulia Ribelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paolo Manca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bruno Vincenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giuseppe Tonini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniele Santini .

Editor information

Editors and Affiliations

  1. Department of Orthopaedics and Trauma Surgery, University Campus Bio-Medico of Rome, Rome, Italy

    Vincenzo Denaro

  2. Department of Orthopaedics and Trauma Surgery, University Campus Bio-Medico of Rome, Rome, Italy

    Alberto Di Martino

  3. General Direction of Health Program, National Ministry of Health of Italy, Rome, Italy

    Andrea Piccioli

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Santini, D. et al. (2019). Bone-Modifying Agents and Anticancer Agents with Bone Effects. In: Denaro, V., Di Martino, A., Piccioli, A. (eds) Management of Bone Metastases. Springer, Cham. https://doi.org/10.1007/978-3-319-73485-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73485-9_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-73484-2

  • Online ISBN: 978-3-319-73485-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation